The synthetic killer peptide KP impairs Candida albicans biofilm in vitro.

PubWeight™: 0.75‹?›

🔗 View Article (PMID 28704490)

Published in PLoS One on July 13, 2017

Authors

Simona Paulone1, Andrea Ardizzoni1, Arianna Tavanti2, Serena Piccinelli1, Cosmeri Rizzato3, Antonella Lupetti3, Bruna Colombari1, Eva Pericolini1, Luciano Polonelli4, Walter Magliani4, Stefania Conti4, Brunella Posteraro5, Claudio Cermelli1, Elisabetta Blasi1, Samuele Peppoloni1

Author Affiliations

1: Department of Diagnostics, Clinical and Public Health Medicine, University of Modena and Reggio Emilia, Modena, Italy.
2: Department of Biology, University of Pisa, Pisa, Italy.
3: Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy.
4: Department of Medicine and Surgery, University of Parma, Parma, Italy.
5: Institute of Public Health, Università Cattolica del Sacro Cuore, Fondazione Policlinico Universitario Agostino Gemelli, Rome, Italy.

Articles cited by this

Mechanisms of resistance to azole antifungal agents in Candida albicans isolates from AIDS patients involve specific multidrug transporters. Antimicrob Agents Chemother (1995) 7.44

Candida infections of medical devices. Clin Microbiol Rev (2004) 4.72

Antifungal susceptibility of Candida biofilms: unique efficacy of amphotericin B lipid formulations and echinocandins. Antimicrob Agents Chemother (2002) 4.52

Candida biofilms: an update. Eukaryot Cell (2005) 3.58

A simple and reproducible 96-well plate-based method for the formation of fungal biofilms and its application to antifungal susceptibility testing. Nat Protoc (2008) 3.46

Growth of Candida albicans hyphae. Nat Rev Microbiol (2011) 3.02

Candida albicans pathogenicity mechanisms. Virulence (2013) 2.60

Genetic control of Candida albicans biofilm development. Nat Rev Microbiol (2010) 2.39

Ras links cellular morphogenesis to virulence by regulation of the MAP kinase and cAMP signalling pathways in the pathogenic fungus Candida albicans. Mol Microbiol (2001) 2.32

Genotypic evolution of azole resistance mechanisms in sequential Candida albicans isolates. Eukaryot Cell (2007) 2.25

Cloning of the Candida albicans homolog of Saccharomyces cerevisiae GSC1/FKS1 and its involvement in beta-1,3-glucan synthesis. J Bacteriol (1997) 2.01

Alternative mating type configurations (a/α versus a/a or α/α) of Candida albicans result in alternative biofilms regulated by different pathways. PLoS Biol (2011) 1.84

Therapeutic potential of antiidiotypic single chain antibodies with yeast killer toxin activity. Nat Biotechnol (1997) 1.75

Characterization of mucosal Candida albicans biofilms. PLoS One (2009) 1.51

A multifunctional, synthetic Gaussia princeps luciferase reporter for live imaging of Candida albicans infections. Infect Immun (2009) 1.48

The human salivary peptide histatin 5 exerts its antifungal activity through the formation of reactive oxygen species. Proc Natl Acad Sci U S A (2001) 1.30

Functional analysis of cis- and trans-acting elements of the Candida albicans CDR2 promoter with a novel promoter reporter system. Eukaryot Cell (2009) 1.02

Internal thiols and reactive oxygen species in candidacidal activity exerted by an N-terminal peptide of human lactoferrin. Antimicrob Agents Chemother (2002) 1.00

Antibody complementarity-determining regions (CDRs) can display differential antimicrobial, antiviral and antitumor activities. PLoS One (2008) 1.00

Fungal infections associated with HIV infection. Oral Dis (2002) 1.00

The natural antimicrobial carvacrol inhibits quorum sensing in Chromobacterium violaceum and reduces bacterial biofilm formation at sub-lethal concentrations. PLoS One (2014) 0.99

A 96 well microtiter plate-based method for monitoring formation and antifungal susceptibility testing of Candida albicans biofilms. J Vis Exp (2010) 0.98

Therapeutic activity of an engineered synthetic killer antiidiotypic antibody fragment against experimental mucosal and systemic candidiasis. Infect Immun (2003) 0.98

Novel anti-infectives: is host defence the answer? Curr Opin Biotechnol (2008) 0.98

Candida albicans biofilm formation and its clinical consequences. Future Microbiol (2009) 0.93

Clinically significant micafungin resistance in Candida albicans involves modification of a glucan synthase catalytic subunit GSC1 (FKS1) allele followed by loss of heterozygosity. J Antimicrob Chemother (2010) 0.92

Peptides of the constant region of antibodies display fungicidal activity. PLoS One (2012) 0.85

Candida albicans biofilms: development, regulation, and molecular mechanisms. Microbes Infect (2016) 0.85

Activity of antimicrobial peptide mimetics in the oral cavity: I. Activity against biofilms of Candida albicans. Mol Oral Microbiol (2010) 0.84

The production of reactive oxygen species is a universal action mechanism of Amphotericin B against pathogenic yeasts and contributes to the fungicidal effect of this drug. Antimicrob Agents Chemother (2014) 0.84

Pathogenesis of Candida albicans biofilm. Pathog Dis (2016) 0.84

Effect of tetrandrine against Candida albicans biofilms. PLoS One (2013) 0.84

Activation of the Cph1-dependent MAP kinase signaling pathway induces white-opaque switching in Candida albicans. PLoS Pathog (2013) 0.83

Killer peptide: a novel paradigm of antimicrobial, antiviral and immunomodulatory auto-delivering drugs. Future Med Chem (2011) 0.83

Derivatives of the mouse cathelicidin-related antimicrobial peptide (CRAMP) inhibit fungal and bacterial biofilm formation. Antimicrob Agents Chemother (2014) 0.83

Synergistic Activity of the Plant Defensin HsAFP1 and Caspofungin against Candida albicans Biofilms and Planktonic Cultures. PLoS One (2015) 0.78

Candida albicans biofilm development on medically-relevant foreign bodies in a mouse subcutaneous model followed by bioluminescence imaging. J Vis Exp (2015) 0.78

The radish defensins RsAFP1 and RsAFP2 act synergistically with caspofungin against Candida albicans biofilms. Peptides (2015) 0.78

Activity of Isavuconazole and Other Azoles against Candida Clinical Isolates and Yeast Model Systems with Known Azole Resistance Mechanisms. Antimicrob Agents Chemother (2015) 0.77

Antimicrobial peptides for the control of biofilm formation. Curr Top Med Chem (2017) 0.76

Antimicrobial Peptides as a Strategy to Combat Fungal Biofilms. Curr Top Med Chem (2017) 0.76

Pathogenic factors in Candida biofilm-related infectious diseases. J Appl Microbiol (2016) 0.76

Human pathogenic viruses are retained in and released by Candida albicans biofilm in vitro. Virus Res (2013) 0.76

Antifungal Therapy: New Advances in the Understanding and Treatment of Mycosis. Front Microbiol (2017) 0.75

Antimicrobial activity, cytotoxicity and chemical analysis of lemongrass essential oil (Cymbopogon flexuosus) and pure citral. Appl Microbiol Biotechnol (2016) 0.75

Inhibition of Candida albicans Biofilm Formation by the Synthetic Lactoferricin Derived Peptide hLF1-11. PLoS One (2016) 0.75

Medical Device-Associated Candida Infections in a Rural Tertiary Care Teaching Hospital of India. Interdiscip Perspect Infect Dis (2016) 0.75

A Naturally Occurring Antibody Fragment Neutralizes Infectivity of Diverse Infectious Agents. Sci Rep (2016) 0.75